Tags

Type your tag names separated by a space and hit enter

Helicobacter pylori, pepsinogen, and risk for gastric adenocarcinoma.
Cancer Epidemiol Biomarkers Prev 1993 Sep-Oct; 2(5):461-6CE

Abstract

The objective of this project was to determine the association of Helicobacter pylori infection and serum pepsinogen levels on subsequent risk for gastric adenocarcinoma. This nested case-control study was set in a large health maintenance organization. One hundred thirty-six cases of gastric adenocarcinoma and 136 matched controls without adenocarcinoma from a large cohort that had contributed serum in the 1960's were studied. The presence of IgG against H. pylori had previously been determined by enzyme-linked immunosorbent assay. Serum levels of pepsinogens I and II were ascertained by radioimmunoassay. In a sample of subjects, the presence of antiparietal cell antibodies was determined by immunofluorescent antibody assay (Nichols Laboratory). There were 98 cases of adenocarcinoma of the antrum, body, or fundus (distal cancers) and 30 of the cardia or gastroesophageal junction (proximal cancers). By univariate analysis, H. pylori infection [odds ratio (OR), 3.6; P < 0.001] and serum pepsinogen I < 50 ng/ml (OR = 2.9; P = 0.003) were both associated with development of distal cancer. In multivariate analysis, there was interaction between the two variables; H. pylori in the absence of low pepsinogen I was independently associated with cancer (OR, 2.4; P = 0.04) but low pepsinogen I in the absence of H. pylori infection was not associated with cancer (OR, 0.8; P > 0.5). In combination, however, H. pylori infection and a low pepsinogen I were associated with a marked increase in the risk of developing distal malignancy (OR, 10.0; P = 0.08).(

ABSTRACT

TRUNCATED AT 250 WORDS)

Authors+Show Affiliations

Department of Medicine, Stanford University, California 94305.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, P.H.S.

Language

eng

PubMed ID

8220091

Citation

Parsonnet, J, et al. "Helicobacter Pylori, Pepsinogen, and Risk for Gastric Adenocarcinoma." Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored By the American Society of Preventive Oncology, vol. 2, no. 5, 1993, pp. 461-6.
Parsonnet J, Samloff IM, Nelson LM, et al. Helicobacter pylori, pepsinogen, and risk for gastric adenocarcinoma. Cancer Epidemiol Biomarkers Prev. 1993;2(5):461-6.
Parsonnet, J., Samloff, I. M., Nelson, L. M., Orentreich, N., Vogelman, J. H., & Friedman, G. D. (1993). Helicobacter pylori, pepsinogen, and risk for gastric adenocarcinoma. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored By the American Society of Preventive Oncology, 2(5), pp. 461-6.
Parsonnet J, et al. Helicobacter Pylori, Pepsinogen, and Risk for Gastric Adenocarcinoma. Cancer Epidemiol Biomarkers Prev. 1993;2(5):461-6. PubMed PMID: 8220091.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Helicobacter pylori, pepsinogen, and risk for gastric adenocarcinoma. AU - Parsonnet,J, AU - Samloff,I M, AU - Nelson,L M, AU - Orentreich,N, AU - Vogelman,J H, AU - Friedman,G D, PY - 1993/9/1/pubmed PY - 1993/9/1/medline PY - 1993/9/1/entrez SP - 461 EP - 6 JF - Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology JO - Cancer Epidemiol. Biomarkers Prev. VL - 2 IS - 5 N2 - The objective of this project was to determine the association of Helicobacter pylori infection and serum pepsinogen levels on subsequent risk for gastric adenocarcinoma. This nested case-control study was set in a large health maintenance organization. One hundred thirty-six cases of gastric adenocarcinoma and 136 matched controls without adenocarcinoma from a large cohort that had contributed serum in the 1960's were studied. The presence of IgG against H. pylori had previously been determined by enzyme-linked immunosorbent assay. Serum levels of pepsinogens I and II were ascertained by radioimmunoassay. In a sample of subjects, the presence of antiparietal cell antibodies was determined by immunofluorescent antibody assay (Nichols Laboratory). There were 98 cases of adenocarcinoma of the antrum, body, or fundus (distal cancers) and 30 of the cardia or gastroesophageal junction (proximal cancers). By univariate analysis, H. pylori infection [odds ratio (OR), 3.6; P < 0.001] and serum pepsinogen I < 50 ng/ml (OR = 2.9; P = 0.003) were both associated with development of distal cancer. In multivariate analysis, there was interaction between the two variables; H. pylori in the absence of low pepsinogen I was independently associated with cancer (OR, 2.4; P = 0.04) but low pepsinogen I in the absence of H. pylori infection was not associated with cancer (OR, 0.8; P > 0.5). In combination, however, H. pylori infection and a low pepsinogen I were associated with a marked increase in the risk of developing distal malignancy (OR, 10.0; P = 0.08).(ABSTRACT TRUNCATED AT 250 WORDS) SN - 1055-9965 UR - https://www.unboundmedicine.com/medline/citation/8220091/Helicobacter_pylori_pepsinogen_and_risk_for_gastric_adenocarcinoma_ L2 - http://cebp.aacrjournals.org/cgi/pmidlookup?view=long&amp;pmid=8220091 DB - PRIME DP - Unbound Medicine ER -